TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported Aug 28 2014 - Updated Aug 29 2014 - 2 reports

NICE nod for Biogen’s MS drug after price reduction

Biogen Idec’s MS drug has been granted NICE approval following a price reduction, with the treatment available on a patient-access scheme across England and Wales.In final guidance recently released by the National Institute for Health and Care Excellence ... [Published Pharma Field - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 1 reports

Five things for Pharma Marketers to know: Wednesday, August 27

Share this article:Allergan has set a date for a Valeant faceoffAllergan has set a date for a Valeant faceoff: Allergan, the manufacturer of multi-indicated Botox has set December 18 as the day shareholders will have the opportunity to vote to replace ... [Published Medical Marketing And Media - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 2 reports

NHS go ahead for new MS treatment

28th August 2014 – Multiple sclerosis patients in England and Wales will become eligible to receive the new medication dimethyl fumarate on the NHS by late November following final guidance from the National Institute for Health and Care Excellence ( ... [Published BootsWebMD - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 5 reports

Biogen Idec's Tecfidera receives NICE recommendation

:07 in Pharmaceutical Company Product News Biogen Idec's new multiple sclerosis (MS) therapy Tecfidera has been approved for NHS use by the National Institute for Health and Care Excellence (NICE). In final guidance from the UK regulator, the dimethyl ... [Published Zenopa - Aug 28 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

New oral MS treatment Tecfidera approved for use in Northern Ireland

The Northern Ireland Health and Social Care Board has announced that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Northern Ireland. The Board reached its decision after reviewing the evidence on the ... [Published MS News - Aug 22 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

US FDA approves Biogen’s MS drug

Singapore: The US food and Drug Administration (FDA) has approved Biogen's multiple sclerosis (MS) drug, Plegridy (peginterferon beta-1a). The drug is for relapsing forms of MS, taken once every two weeks. The treatment, which has got the thumbs-up based ... [Published Bio Spectrum Asia - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 5 reports

Biogen twice-monthly MS drug approved

Share this article: The FDA has given the go-ahead to Biogen Idec's twice-a-month MS treatment Plegridy (peginterferon beta-1a). The approval makes this the only pegylated beta-interferon drug approved for relapsing multiple sclerosis. The injectable ... [Published Medical Marketing And Media - Aug 18 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 2 reports

Solid quarter for Merck KGaA but Rebif under pressure

Merck KGaA has posted a reasonable set of financials for the second quarter, although competition from oral therapies is beginning to hurt sales of the German firm’s multiple sclerosis drug Rebif.Net income was down 4.1% to 303.3 million euros, while ... [Published Pharma Times - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar Tecfidera

Biogen Idec's ( $BIIB ) multibillion-selling multiple sclerosis drug Tecfidera is grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its own product. It says it is looking at a $200 ... [Published FiercePharma - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised

First reported Aug 07 2014 - Updated Aug 07 2014 - 4 reports

TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 (Canada NewsWire via COMTEX) -- ... [Published Individual.com - Aug 07 2014]
Entities: TECFIDERA, Comtex, Canada
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Shares Of Biogen Idec, Inc. (Massachusetts) Slip As Tecfidera Hits Second Hurdle In Germany

Shares of Biogen Idec dropped slightly Friday after the biopharma giant hit a second hurdle in Europe over its multiple sclerosis drug Tecfidera, a product Biogen hopes to soon produce in the Triangle.German regulators determined that Tecfidera provided ... [Published BioSpace - Aug 04 2014]

Quotes

"The last twelve months have seen a significant improvement in treatment options for people with relapsing remitting MS. While there are treatments to help manage symptoms, there are no disease modifying treatments available for people with progressive MS. We continue to urge scientists and clinicians to pursue this hugely important area of research for MS."
"For more than 30 years, Biogen Idec has been committed to improving the lives of people living with MS. Biogen Idec is dedicated to serving all those affected by the disease through cutting-edge science and delivering innovative therapies, all enhanced by a deep understanding of patients' needs."
...According to UBS figures, half of the Copaxone prescriptions in July were for the 40-mg version. "The transfer of patients is continuing successfully. Given the fact that Teva has filed another petition with the FDA asking for more figures from the generic companies, there is likely to be more delay before a generic version of Copaxone is approved. This delay will help Teva transfer more patients" wrote analyst Mark Goodman. Managed by Erez Vigodman, Teva is traded at a $45.6 billion market cap
"Regarding this issue I am not sure of what is the correct answer, except to say that Pharma will charge as much as the market will support. This means we need systems in place to keep the prices reasonable, which is what EU organisations such as NICE do. However,  this does not occur in the US and hence the costs of drugs in the US is much higher than outside of the US. This means that the US is subsiding drug prices, and drug development, for the rest of the world. The latter cannot go on indefinitely. What is a problem is when the new drugs are truly transformational and without them people with certain disease will die. This issue has recently been raised with the pricing of the new hepatitis C drugs and I have addressed this on the blog quite recently. Similarly, should Pharma bosses get paid so much? For example John Martin, the CEO of Gilead who make the new hepatitis C drug, received $90 million in 2012. Economists would argue that if you believe in the power of the market to deliver then you should let it work its magic; if you try and prevent the market working it won't deliver on what is needed. I am not sure if buying and prescribing of drugs is a real market; sick people don't have a choice when it comes to certain treatments. What do you think? Is the prescription drug market a real market?"

More Content

All (186) | News (121) | Reports (1) | Blogs (63) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
NICE nod for Biogen’s MS drug after price reduc... [Published Pharma Field - Aug 29 2014]
NICE recommends Tecfidera [Published Pharmaceutical Journal - Aug 28 2014]
NHS go ahead for new MS treatment [Published BootsWebMD - Aug 28 2014]
Biogen Idec's Tecfidera receives NICE recommend... [Published Zenopa - Aug 28 2014]
NICE recommends new treatment option for multip... [Published FirstWord Pharma - Aug 27 2014]
Biogen's Eloctate Approved in Canada for Hemoph... [Published Zacks.com - Aug 27 2014]
NICE recommends Biogen Idec’s Tecfidera for mul... [Published Pharma Letter - Aug 27 2014]
Dimethyl fumarate (BG-12, Tecfidera) - NICE con... [Published Multiple Sclerosis Trust - Aug 27 2014]
Five things for Pharma Marketers to know: Wedne... [Published Medical Marketing And Media - Aug 27 2014]
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 27 2014]
Final NICE backing for Tecfidera [Published PMLive - Aug 27 2014]
NICE backs new oral tablet treatment for multip... [Published Nursing Times - Aug 27 2014]
NICE confirms recommendation for Biogen MS pill [Published Pharma Times - Aug 27 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 26 2014]
FDA Approves Biogen Idec's MS Drug Plegridy [Published FDA News - Aug 26 2014]
New Biogen MS drug challenges Copaxone [Globes,... [Published BusinessWeek - Aug 24 2014]
The $76 Billion CVS Business You've Probably Ne... [Published Motley Fool - Aug 24 2014]
New Biogen MS drug challenges Copaxone [Published Globes - Aug 24 2014]
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 22 2014]
Pharma ETF Investing 101 [Published Yahoo! Finance - Aug 21 2014]
Company Update: Biogen Idec Inc (NASDAQ:BIIB) –... [Published Jutia Group - Aug 21 2014]
Interferons vs. Copaxone: how do they compare? [Published MSology - Aug 21 2014]
Price could be key for Sanofi's new Gaucher pil... [Published FiercePharma - Aug 20 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published 24/7 Wall St - Aug 20 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published Yahoo! Xtra Business - Aug 20 2014]
dimethyl fumarate (Tecfidera) [Published MedicineNet.com - Aug 20 2014]
US FDA approves Biogen’s MS drug [Published Bio Spectrum Asia - Aug 20 2014]
FDA okays Genzyme pill for Gaucher disease [Published Boston Globe - Aug 19 2014]
Biogen Strengthens MS Portfolio with Plegridy F... [Published Nasdaq - Aug 19 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 27 2014]
Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence ( NICE ) has announced.  The NHS must now begin funding this treatment for eligible ...
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ...
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 22 2014]
The Northern Ireland Health and Social Care Board has announced that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Northern Ireland. The Board reached its decision after reviewing the evidence on the ...
Interferons vs. Copaxone: how do they compare? [Published MSology - Aug 21 2014]
Beta-interferon drugs (Avonex, Betaseron/Extavia, Rebif) and Copaxone have been the mainstay of treatment for MS for over two decades. What they have in common is very modest effectiveness, and the need to be injected. But is one type of treatment better ...
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ...
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.